MOREPENLAB Morepen Laboratories Q4 FY25 results (Jan–Mar 2025) and concall
Morepen Labs reported a resilient FY25 with revenue growth of 7.4% and strong EBITDA and PAT increases despite a challenging Q4. The company is strategically focusing on higher-margin finished dosages and medical devices, alongside significant capacity expansions in both API and devices. While API prices faced pressure, management believes they are bottoming out, setting a positive outlook for future margin improvement and overall growth.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q3 FY25 | Q4 FY25 |
|---|---|---|
| Revenue | 403 | 382 |
| EBITDA | 32 | 30 |
| Net profit | 23 | 12 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
